Clinical Trials Browser

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

NCT07526493 2026-04-13

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06680037 2026-04-07

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Phase 1 Recruiting

32 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT00716066 2026-02-27

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Phase 2 Active not recruiting

53 enrolled

CNS

Rasmussen subacute encephalitis, Autoimmune Diseases, Myasthenia Gravis, Neuromyelitis Optica, Lambert-Eaton Myasthenic Syndrome, Stiff-Person Syndrome, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Vasculitis, Central Nervous System, Opsoclonus-Myoclonus Syndrome

NCT07392528 2026-02-11

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Phase EARLY_PHASE1 Not yet recruiting

15 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica

NCT07333196 2026-01-21

Tongji NADs Cohort

Not yet recruiting

1,550 enrolled

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Guillain-Barre Syndrome, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT01623076 2026-01-06

The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders

Active not recruiting

150 enrolled

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

NCT06939166 2025-12-15

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

Phase EARLY_PHASE1 Recruiting

12 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT04201262 2025-10-14

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Phase 3 Completed

58 enrolled 19 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

NCT00445367 2025-10-02

Biobank For MS And Other Demyelinating Diseases

Active not recruiting

3,226 enrolled

Encephalomyelitis, Acute Disseminated, Multiple Sclerosis, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

NCT06249438 2025-07-25

CAR-AID

Phase 1 Recruiting

30 enrolled

Lupus Erythematosus, Systemic, Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Scleroderma, Systemic

NCT07022197 2025-06-15

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Phase 1/2 Recruiting

27 enrolled

Myasthenia Gravis, Myositis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06941584 2025-04-24

NAD-AIRE

Recruiting

40 enrolled

Myasthenia Gravis, Neuromyelitis Optica, Polyendocrinopathies, Autoimmune, Autoimmune Diseases of the Nervous System, Isaacs Syndrome

NCT06485232 2025-01-01

Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.

Phase EARLY_PHASE1 Not yet recruiting

25 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT05017142 2024-12-16

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Recruiting

500 enrolled

CNS

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Encephalitis, Encephalomyelitis, Acute Disseminated, Multiple Sclerosis, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Autoimmune Diseases of the Nervous System, Vasculitis, Central Nervous System, Lupus Vasculitis, Central Nervous System, Anti-N-Methyl-D-Aspartate Receptor Encephalitis

NCT06502015 2024-11-20

Biomarkers in Autoimmune Disease of Nervous System

Recruiting

50,000 enrolled

Autoimmune Diseases, Encephalomyelitis, Acute Disseminated, Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Stiff-Person Syndrome, Autoimmune Diseases of the Nervous System, Guillain-Barre Syndrome, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT04561557 2024-10-30

CARTinNS

Phase EARLY_PHASE1 Recruiting

36 enrolled

Plasma cell

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Autoimmune Diseases, Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, POEMS Syndrome, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT04155424 2024-09-25

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

Phase 2/3 Terminated

5 enrolled 15 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

NCT06443333 2024-06-05

NIDBase

Recruiting

7,000 enrolled

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Encephalomyelitis, Acute Disseminated, Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System

NCT03942952 2023-09-05

SONICS

Completed

49 enrolled

Encephalomyelitis, Acute Disseminated, Multiple Sclerosis, Myelitis, Transverse, Neuromyelitis Optica, Multiple Sclerosis, Relapsing-Remitting

NCT02003144 2022-08-23

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Phase 3 Completed

119 enrolled 17 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

NCT05245344 2022-02-17

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

Unknown

154 enrolled

Neuromyelitis Optica, Epstein-Barr Virus Infections, Multiple Sclerosis, Relapsing-Remitting

NCT00304291 2020-12-28

A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)

Phase 4 Completed

5 enrolled

Myelitis, Transverse, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS

NCT01892345 2019-06-26

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Phase 3 Terminated

143 enrolled 18 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Phase 1 Completed

6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

NCT03138421 2019-01-25

Central Pain Study for ABX-1431

Phase 1 Completed

9 enrolled

Multiple Sclerosis, Myelitis, Transverse, Neuromyelitis Optica

NCT02166346 2018-04-17

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Phase 2 Completed

24 enrolled 10 charts

Myelitis, Myelitis, Transverse, Neuromyelitis Optica

NCT02398994 2016-07-20

STRIVE

Phase 3 Terminated

2 enrolled

Myelitis, Transverse, Neuromyelitis Optica

NCT00501748 2011-09-27

Safety and Tolerability of Rituximab in Neuromyelitis Optica

Phase 1 Completed

20 enrolled

Myelitis, Transverse, Neuromyelitis Optica

NCT00004645 2005-06-24

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone

Phase 3 Unknown

22 enrolled

Mental Disorders, Diffuse Cerebral Sclerosis of Schilder, Encephalomyelitis, Acute Disseminated, Multiple Sclerosis, Myelitis, Transverse, Neurologic Manifestations, Neuromyelitis Optica, Rare Diseases

Clinical Trials

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Tongji NADs Cohort

The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Biobank For MS And Other Demyelinating Diseases

CAR-AID

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

NAD-AIRE

Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Biomarkers in Autoimmune Disease of Nervous System

CARTinNS

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

NIDBase

SONICS

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Central Pain Study for ABX-1431

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

STRIVE

Safety and Tolerability of Rituximab in Neuromyelitis Optica

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone